Micro-costing study of rituximab subcutaneous injection versus intravenous infusion in dutch setting
Background: Rituximab for subcutaneous (SC) administration has recently been approved for use in common forms of diffuse large B-cell lymphoma (DLBCL). This form of rituximab is supplied in ready-to-use vials that do not require individual dose adjustment. It is expected that SC-injection will shorten the treatment time per administration of rituximab in comparison with currently available intravenous (IV) infusion. Aims: The goal of this study is to identify and compare all direct costs of IV and SC rituximab given to the DLBCL patients in the Netherlands. Methods: Using a prospective, observ... Mehr ...
Verfasser: | |
---|---|
Dokumenttyp: | Artikel |
Erscheinungsdatum: | 2015 |
Reihe/Periodikum: | Mihajlović , J , Bax , P , Van Breugel , E , Blommestein , H M , Hoogendoorn , M , Hospes , W & Postma , M J 2015 , ' Micro-costing study of rituximab subcutaneous injection versus intravenous infusion in dutch setting ' , Haematologica , vol. 100 , pp. 582 . |
Schlagwörter: | rituximab / subcutaneous drug administration / intravenous drug administration / European / hematology / injection / Netherlands / day care / spillage / drug cost / large cell lymphoma / patient / human / population |
Sprache: | Englisch |
Permalink: | https://search.fid-benelux.de/Record/base-26671172 |
Datenquelle: | BASE; Originalkatalog |
Powered By: | BASE |
Link(s) : | https://hdl.handle.net/11370/7c52057b-a2b3-45cf-b803-e8631f648cd3 |